drugset / Trial / NCT00294112

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

NCT00294112

Phase 2 Completed 10 enrolled Mesoblast, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair. Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms.

Timeline

Start
2006-03-13
Primary completion
2006-07-21
Completion
2006-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Prochymal® Cell therapy 2e+06 cells/kg Intravenous
Subject Prochymal® Cell therapy 8e+06 cells/kg Intravenous

Indications